Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU.
about
68Ga-Based radiopharmaceuticals: production and application relationshipCharacterization of [(99m)Tc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis.Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.Prospective of ⁶⁸Ga-radiopharmaceutical development.Feasibility and availability of ⁶⁸Ga-labelled peptides.Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomographyUsing PET for therapy monitoring in oncological clinical trials: challenges ahead.68Ga-DOTA and analogs: Current status and future perspectivesRadiation Dosimetry of a Novel Adenosine A2A Receptor Radioligand [11C]Preladenant Based on PET/CT Imaging and Ex Vivo Biodistribution in Rats.Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H.Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study.Why are we failing to implement imaging studies with radiolabelled new molecular entities in early oncology drug development?Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals.Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma.Use of LC-MS for the quality control of radiopharmaceuticals: example of [(18)F]ML10.The role of quality management system in the monitoring and continuous improvement of GMP-regulated short-lived radiopharmaceutical manufactureImplementation of Good Manufacturing Practice in small-volume production of [18F]FDG: a case report of performance measurements
P2860
Q26801794-B46FA69A-75EB-472F-9E30-C574615AE524Q36269742-0E6512AE-9997-4304-88DD-0120319FDDA1Q36609881-0C259B43-BD84-4A0B-9A1F-DF192C8709FDQ37435222-AA976949-9BE9-4AA9-BFFF-C55473809CDDQ37990396-ED323D70-6D44-49EA-8050-4360245A8C76Q38244707-84AA2950-B64D-4B77-A60C-FAE503778357Q38689940-3FE1352B-09DA-46D1-B7D3-F961296412E6Q39191325-CC3DC77D-DEE3-432C-A09F-CB7B59030BC0Q39475901-82E66A5D-04C6-4F5A-ABB7-4BD2C8F95EB2Q40739953-39E4394C-AF6C-4723-A4FE-C1DD8EAB2CDFQ41083360-C0378CA6-C4D2-447C-B936-33BCC9A3B9ADQ41571892-20D3B040-33F2-4C8C-A705-2409DA14D41AQ51207076-915CF711-0981-4F8F-8639-FFA7F28CD006Q51817347-1ADCF137-0662-4134-9324-7689755B301EQ53102538-40B6BDC4-0AB2-4330-B15B-E5F4CC3A9C37Q54523609-54A27F57-8A85-4F68-A7F1-4088683B59FFQ57730685-19CE2627-EA6C-49E0-964A-84381E027919Q57730744-529268A3-37D0-4B22-8A80-0E3A6F8A0BC0
P2860
Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Guideline to regulations for r ...... ase clinical trials in the EU.
@en
Guideline to regulations for r ...... ase clinical trials in the EU.
@nl
type
label
Guideline to regulations for r ...... ase clinical trials in the EU.
@en
Guideline to regulations for r ...... ase clinical trials in the EU.
@nl
prefLabel
Guideline to regulations for r ...... ase clinical trials in the EU.
@en
Guideline to regulations for r ...... ase clinical trials in the EU.
@nl
P2093
P50
P1476
Guideline to regulations for r ...... ase clinical trials in the EU.
@en
P2093
Alfons Verbruggen
Heinz H Coenen
Jean-Robert Deverre
P2888
P304
P356
10.1007/S00259-008-0853-7
P577
2008-11-01T00:00:00Z